[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"General University Hospital, Prague\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":398},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,39,69,92,119,145,165,186,215,244,272,303,326,348,371],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100634887","hpv-testing-as-a-prevention-of-cervical-dysplasia-and-cancer-before-planned-subtotal-hysterectomy-100634887",false,"NCT07545525","HPV Testing as a Prevention of Cervical Dysplasia and Cancer Before Planned Subtotal Hysterectomy","HPV Testing as a Prevention of Cervical Dysplasia and Cervical Cancer Before Planned Subtotal Hysterectomy","Inclusion Criteria:\n\n* age over 18\n* indication for subtotal hysterectomy\n* consent to provide conisation in case the HPV test result is positive\n\nExclusion Criteria:\n\n* negative HPV test in the last 3 years","FEMALE","18 Years",{"count":19,"type":20},300,"ESTIMATED","6 Months","OBSERVATIONAL","Patients indicated for subtotal hysterectomy will be tested for High risk HPV and if the result is positive will undergo expert colposcopy and conisation if not indicated otherwise at the time of subtotal hysterectomy",[25,26],"Cervical Cancer Screening","Human Papilloma Virus (HPV)","NOT_YET_RECRUITING","2026-04-21",{"date":30,"type":31},"2026-04-22","ACTUAL",{"date":33,"type":20},"2026-04",{"date":35,"type":20},"2029-04",{"name":37,"class":38},"General University Hospital, Prague","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":55,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100630919","hpv-after-chemoradiotherapy-100630919","NCT07493928","HPV After chemoRadioTherapy","Implementation of HPV Testing in Patients After Radiotherapy for Cervical Cancer","HART","Inclusion Criteria:\n\n* Patient indicated for primary RT for cervical cancer\n* FIGO stage IB - IVA\n* Signed informed consent\n* Age ≥ 18 years\n* Administration of RT with curative intent\n\nExclusion Criteria:\n\n* Clinical stage FIGO IA\n* Clinical stage FIGO IVB\n* History of radiotherapy in the pelvis\n* Hysterectomy performed before the start of radiotherapy (adjuvant RT)\n* History of HPV-associated malignancy in personal history\n* HIV or other significant immunodeficiency",{"count":48,"type":20},120,"The HART (HPV After chemoRadiotherapy) study is a prospective multicenter observational trial designed to evaluate the clinical utility of HPV testing in the follow-up of patients treated with definitive chemoradiotherapy (CRT) for cervical cancer. Current surveillance after CRT relies mainly on clinical examination and imaging, while the role of HPV-based molecular monitoring remains insufficiently defined. The study plans to enroll 120 patients with FIGO stage IB-IVA cervical cancer treated with primary radiotherapy with curative intent. HPV detection will be performed using two complementary approaches: PCR-based detection of HPV DNA from a cervical swab and analysis of circulating HPV tumor DNA (ctDNA) in peripheral blood. Samples will be collected before treatment and during follow-up at 3, 12, and 24 months after completion of CRT. The primary objective is to determine the sensitivity of these methods for detecting disease recurrence during a two-year follow-up period. Secondary objectives include evaluation of HPV clearance after treatment, comparison of HPV genotypes before and after therapy in cases of persistence, and comparison of the diagnostic performance of cervical HPV testing and ctDNA detection. The study aims to generate evidence supporting the integration of HPV-based molecular monitoring into routine follow-up, potentially enabling earlier detection of recurrence and more individualized surveillance strategies for patients after CRT for cervical cancer.",[51,52,53,54],"Cervical Cancer Recurrent","Radiotherapy","Cell Free DNA","HPV",[56,57,58],"cervical cancer","cfDNA","radiotherapy","RECRUITING","2026-03-20",{"date":62,"type":31},"2026-03-25",{"date":64,"type":31},"2026-02-01",{"date":66,"type":20},"2030-02-01",{"name":37,"class":38},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":78,"studyType":22,"phases":4,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":68},"100527409","regression-of-cervical-precancerous-lesions-and-associated-risk-factors-100527409","NCT06147388","Regression of Cervical Precancerous Lesions and Associated Risk Factors","RECER","Inclusion Criteria:\n\n1. squamocolumnar junction fully visualized\n2. bioptically verified CIN 2 or CIN 3\n3. age ≥ 18 years\n4. age ≤ 40 years\n5. informed consent\n\nExclusion Criteria:\n\n1. squamocolumnar junction not fully visualized\n2. suspicion on glandular lesion\n3. suspicion on invasive cancer\n4. personal history of CIN 2, 3 or cerv. cancer\n5. gravidity\n6. HIV positivity\n7. immunosuppression\n8. impossible photographic documentation","40 Years",{"count":19,"type":20},"2 Years","The aim of this study is to assess the extent of histopathological regression of severe cervical precancerous lesions (CIN 2 and CIN 3); evaluate the proportion of patients who experience the normalization of HPV test and cytology finding among those who were treated conservatively and those who underwent conization; and identify predictive parameters associated with regression. Based on this analysis, a model will be proposed to predict the likelihood of lesion regression.",[81,54,82,83],"Cervix Uteri SIL","CIN2","CIN3","2026-02-22",{"date":86,"type":31},"2026-02-25",{"date":88,"type":31},"2022-09-01",{"date":90,"type":20},"2027-07-01",{"name":37,"class":38},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":68},"100613600","expiratory-muscle-training-in-parkinsons-disease-with-forward-trunk-flexion-100613600","NCT07268703","Expiratory Muscle Training in Parkinson's Disease With Forward Trunk Flexion","Effect of Expiratory Muscle Strength Training in Patients With Parkinson's Disease and Forward Trunk Flexion: A Pilot Study","Inclusion Criteria:\n\n* Diagnosis of Parkinson' s disease\n* Age ≥ 18 years\n* MoCA score (Montreal Cognitive Assessment) ≥ 19\n* Score II-IV during the \"ON\" phase under regular antiparkinsonian medication according to the Modified Hoehn and Yahr Scale\n* Pathological forward trunk flexion defined as thoracic (≥ 25°) or lumbar flexion (\\> 15°) during standing and walking, which completely disappears in the supine position (for the experimental group only)\n\nExclusion Criteria:\n\n* Change in antiparkinsonian medication within the last 3 months prior to study enrollment\n* Other neurological, orthopedic, cardiovascular, or respiratory comorbidities\n* Inability to cooperate due to neuropsychological dysfunction\n* Current smoking history\n* Inadequate lip seal","ALL",{"count":101,"type":20},28,"INTERVENTIONAL",[104],"NA","Postural abnormalities (PA) negatively affecting the axial system are part of the symptoms of Parkinson's disease (PD). They occur in more than 20% of patients with PD especially in more advanced stages of the disease, contribute significantly to patient disability, affect respiratory functions, and reduce quality of life. Eighty-five percent of patients with forward trunk flexion (FTF) reported difficulties with swallowing (dysphagia), shortness of breath, and drooling. Previous studies in patients with PD also identified cough disorders (dystussia). Since cough and properly functioning swallowing are key mechanisms for airway protection, impairments in these functions lead to a higher risk of aspiration. The seriousness of this problem is clearly confirmed by the fact that aspiration pneumonia is the leading cause of death in patients with PD.\n\nAmong non-pharmacological interventions for airway protection, expiratory muscle strength training (EMST) has been shown to be beneficial in patients with PD. Recent randomized controlled studies demonstrated a significant effect of EMST on dysphagia, dystussia, drooling, and dysarthria in patients with PD.\n\nHowever, the literature lacks data on the effect of EMST on dystussia in patients with PD and FTF, who, according to previous research, are also affected by restrictive ventilatory impairment, which negatively affects respiratory capacity and, in particular, cough strength.\n\nThe aim of this study is to evaluate the effect of EMST on cough, swallowing, respiratory muscle strength, and drooling in patients with PD and forward trunk flexion.",[107],"Parkinson's Disease",[107,109,110],"Expiratory Muscle Strength Training","Forward Trunk Flexion","2025-11-25",{"date":113,"type":31},"2025-12-08",{"date":115,"type":20},"2025-12",{"date":117,"type":20},"2026-05",{"name":37,"class":38},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":99,"minAge":76,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":102,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},"100588525","effect-of-visual-feedback-from-the-spirogym-mobile-application-100588525","NCT06942533","Effect of Visual Feedback From the SpiroGym Mobile Application","The Effect of Visual Feedback From the SpiroGym Mobile Application on Expiratory Muscle Strength Training Performance in Patients With Parkinson's Disease","EXPARK","Inclusion Criteria:\n\n* Diagnosis of Parkinsons disease\n* Stable dopaminergic medication (stable dose for at least 1 month)\n\nExclusion Criteria:\n\n* Other neurological disorders\n* Significant cognitive impairment\n* Major psychiatric disorder\n* History of head or neck cancer or previous surgical interventions in the neck region.\n* Illness during the study period","80 Years",{"count":129,"type":20},30,[104],"The previous pilot study showed that two weeks of intensive expiratory muscle strength training (EMST) with SpiroGym was sufficient to significantly improve voluntary peak cough flow (PCF). The improvement was quantitatively comparable to that reported in other intensive EMST studies of longer duration. To explain this rapid improvement, we considered the potential contribution of SpiroGym's visual feedback. We assumed that real-time visual feedback increased training effort compared with conventional EMST performed without immediate feedback.\n\nThe aim of this study is to evaluate the effect of visual feedback provided by the SpiroGym mobile application on performance during expiratory muscle strength training in patients with Parkinson's disease.",[133,134,135],"Parkinson Disease","Breathing Exercises","Telemedicine","2025-11-24",{"date":138,"type":31},"2025-12-01",{"date":140,"type":31},"2025-05-01",{"date":142,"type":20},"2026-07-01",{"name":37,"class":38},2,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":102,"phases":153,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":68},"100590169","expiratory-muscle-training-and-trunk-flexion-in-parkinsons-disease-100590169","NCT06963918","Expiratory Muscle Training and Trunk Flexion in Parkinson's Disease","Effect of Expiratory Muscle Strength Training on Forward Trunk Flexion in Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of Parkinson's Disease\n* Age ≥ 18 years\n* MoCA (Montreal Cognitive Assessment) score ≥19\n* Pathological forward trunk flexion defined as thoracic (≥25°) or lumbar (\\>15°) flexion during standing and walking, which completely disappears in the supine position.\n\nExclusion Criteria:\n\n* Severe dyskinesia or \"on-off\" fluctuations\n* Change in the PD medication in the last 3 months prior to enrollment\n* History of major spinal surgery or musculoskeletal spinal disorders\n* Need for assistive devices when rising from a chair or bed\n* Other neurological, orthopedic, or cardiovascular comorbidities that could affect postural control\n* Inadequate lip seal.",{"count":129,"type":20},[104],"Postural abnormalities involving the trunk are prevalent in over 20% of patients with Parkinson's disease (PD). Pathological forward trunk flexion (FTF) is a drug-refractory complication in patients with PD leading to imbalance, pain and fall-related injuries. Deep abdominal muscle training is a key rehabilitation strategy for FTF, as muscles like the transversus abdominis and multifidus are crucial for lumbar stabilization. This training has been shown to improve body position and lumbar proprioception.\n\nAbdominal muscles are also responsible for forced expiration. Expiratory muscle strength training (EMST) utilizing forced expiration through expiratory trainer has emerged as a beneficial intervention in the non-pharmacological management of PD, positively impacting clinical aspects such as dysphagia, dystussia, hypokinetic dysarthria, and drooling. EMG study showed large abdominal muscles activity, particularly the transversus abdominis and internus obliquus abdominis during EMST. Therefore, EMST might also be effective in improving lumbar stabilization.\n\nGiven the established role of abdominal muscles in trunk stabilization, it is plausible that activation of deep abdominal muscles during EMST with the right level of resistance might improve FTF in PD patients. No studies have yet examined the effect of EMST on posture in PD.\n\nThe primary aim of this study will be to evaluate the effect of EMST on forward trunk flexion in patients with Parkinson's disease.\n\nThe secondary aim will be to assess the potential duration of the EMST effect on postural abnormalities and its impact on patient stability.",[133],[133,109,110],"2025-04-30",{"date":159,"type":31},"2025-05-09",{"date":161,"type":20},"2025-08",{"date":163,"type":20},"2026-01",{"name":37,"class":38},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":68},"100589512","effect-of-trunk-flexion-on-airway-defense-in-parkinsons-disease-100589512","NCT06955377","Effect of Trunk Flexion on Airway Defense in Parkinson's Disease","Effect of Forward Trunk Flexion in Patients With Parkinson's Disease on the Airway Defense System","Inclusion Criteria:\n\n* Diagnosis of Parkinson' s disease\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Unreliable performance of MIP, MEP, or grip strength measurements, for example, due to cognitive deficits (assessed by the researcher)\n* Inadequate lip seal\n* Significant deformities of the dominant hand that could affect the accuracy of grip strength measurements\n* Other severe neurological diseases apart from PD\n* History of unstable cardiovascular disease\n* Severe pulmonary disease",{"count":173,"type":20},100,"The main mechanisms of airway protection include a properly functioning swallowing process and a cough. Studies focusing on patients with Parkinson's disease (PD) have previously demonstrated impairments in both swallowing (dysphagia) and coughing (dystussia). Aspiration pneumonia is the leading cause of death in individuals with PD.\n\nSwallowing function is directly related to body posture. Postural abnormalities (PA) are a common symptom of PD and significantly contribute to patient disability, affect respiratory function, and reduce quality of life. Previous research has shown that more than 20% of PD patients suffer from some form of PA.\n\nMost PD patients with a forward trunk flexion angle greater than 30 degrees report specific difficulties, such as dysphagia. A link has previously been demonstrated between postural abnormalities associated with flexed posture and restrictive ventilatory impairment. It can be assumed that this restrictive ventilatory impairment, which reduces the amount of air the patient can inhale into the lungs and subsequently exhale, negatively affects the strength of voluntary cough. However, this hypothesis has not yet been verified in the mentioned patient group.\n\nThe primary aim of the study will be to examine the effect of forward trunk flexion (FTF) in Parkinson's disease on the airway defense system.",[133],[133,177,178],"Postural abnormalities","Airway defense system",{"date":180,"type":31},"2025-05-02",{"date":182,"type":31},"2025-02-18",{"date":184,"type":20},"2029-02",{"name":37,"class":38},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":102,"phases":196,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":68},"100584723","strength-endurance-circuit-training-in-parkinsons-disease-100584723","NCT06893055","Strength-Endurance Circuit Training in Parkinson's Disease","Strength-Endurance Circuit Training in Parkinson's Disease: Effects on Disease Severity, Physical Performance, Blood Biomarkers and Quality of Life.","Inclusion Criteria:\n\n* age ≥18 years\n* diagnosis of idiopathic Parkinson´s disease\n* Hoehn-Yahr Scale ≤ 2,5\n* stable dopaminergic medication\n\nExclusion Criteria:\n\n* age ≥75 years\n* Hoehn-Yahr Scale ≥ 2,5\n* deep brain stimulation\n* presence of freezing\n* Camptocormia\n* inability to walk without support\n* inability to perform study procedures\n* limiting co-morbidities\n* attendance at training sessions below 70%","75 Years",{"count":195,"type":20},90,[104],"The goal of this clinical trial is to determine whether adding strength training to aerobic training has a comparable or greater effect on the clinical status of Parkinson's disease patients than a standalone aerobic training.\n\n\\- Does combined strength-endurance circuit training provide added benefits to physical performance, disease severity, blood biomarkers, and quality of life in PD patients compared to standalone aerobic training?\n\nParticipants will:\n\n* undergo outcome measurements before and after the 12-week intervention and a 3-month follow-up measurement,\n* visit the clinic twice a week for 1-hour training sessions.\n* selected patients will be given a smartwatch with a pedometer that will count their average number of steps before, during and after the training period",[199],"Parkinson Disease, Idiopathic",[133,201,202,203,204,205,206],"Strength training","Endurance training","Physiotherapy","Irisin","Quality of Life","Physical performance","2025-04-07",{"date":209,"type":31},"2025-04-09",{"date":211,"type":31},"2025-03-03",{"date":213,"type":20},"2027-03",{"name":37,"class":38},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":102,"phases":226,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":68},"100576798","rapid-prehospital-access-to-ecpr-in-prague-100576798","NCT06789978","Rapid Prehospital ACcess to ECPR in Prague","Prehospital Extracorporeal Cardiopulmonary Resuscitation: A Pilot Study in Prague","RACE","Inclusion Criteria:\n\n* Estimated age 18-70 years\n* Refractory out-of-hospital cardiac arrest (3 unsuccessful defibrillations and\u002For at least 10 minutes of resuscitation in case of pulseless electrical activity)\n* Witnessed cardiac arrest\n* ECPR team available\n* ECPR team alert within 20 minutes from the emergency call\n\nExclusion Criteria:\n\n* Unwitnessed cardiac arrest\n* Asystole\n* ETCO2 less than 10 mmHg upon ECPR team arrival\n* Known limitations of intensive care (Do Not Resuscitate - DNR status)\n* Known severe neurological impairment prior to cardiac arrest (mRS 4-6)\n* Suspected or known pregnancy","70 Years",{"count":225,"type":20},20,[104],"A prospective pilot feasibility study of prehospital ECPR in patients with refractory OHCA",[229,230],"Out of Hospital Cardiac Arrest","Extracorporeal Cardiopulmonary Resuscitation",[232,233,234,235],"Cardiac arrest","ECPR","ECMO","Prehospital","2025-02-12",{"date":238,"type":31},"2025-02-14",{"date":240,"type":31},"2025-01-20",{"date":242,"type":20},"2026-06-16",{"name":37,"class":38},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":68},"100578812","tru-cut-biopsy-in-tumor-characterisation-100578812","NCT06816160","TRU-Cut Biopsy in Tumor cHaracterisation","Tru-cut Biopsy in Tumor Characterisation","TRUTH","Inclusion Criteria: Presence of a pelvic\u002Fabdominal lesion with suspicion of malignancy:\n\n1. new diagnosis of a presumed gynecologic tumor\n2. suspicious recurrence or progression of a known gynecologic malignancy\n3. pelvic\u002Fabdominal spread or recurrence of a non-gynecologic tumor (primary tumor or metastasis)\n4. pelvic\u002Fabdominal spread of a tumor of unknown origin 2. Age ≥18 years 3. Eastern Cooperative Oncology Group (ECOG) performance status grade \\\u003C3 4. Not pregnant 5. Signed informed consent form\n\nExclusion Criteria:\n\n1. Considered by the investigator to be unsuitable for any treatment\n2. Early stage disease\n3. Age \\\u003C18 years",{"count":253,"type":20},250,"Tru-cut biopsy (TCB) is a minimally invasive method to get an adequate sample from the lesion in order to tailor the appropriate management avoiding unnecessary surgery. The aim of our trial is to evaluate the adequacy, accuracy and safety of the method related to the final histology as reference standard.",[256],"Tumor",[258,259,260,261,262,263],"tumor","biopsy","tru-cut","core-cut","cancer","pelvic tumor","2025-02-05",{"date":266,"type":31},"2025-02-10",{"date":268,"type":31},"2024-02-01",{"date":270,"type":20},"2027-01-31",{"name":37,"class":38},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":223,"enrollmentInfo":280,"targetDuration":4,"studyType":102,"phases":282,"briefSummary":283,"conditions":284,"keywords":290,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":4},"100577980","the-osiris-ecpr-trial-100577980","NCT06805344","The OSIRIS ECPR Trial","Out-of-hospital Refractory Cardiac Arrest Treated with Extracorporeal Cardiopulmonary Resuscitation","OSIRIS","Inclusion Criteria:\n\n1. Age ≥18 and ≤ 70 years presumed or known\n2. Witnessed OHCA\n3. Bystander CPR provided\n4. Presumed cardiac or unknown cause\n5. An initial documented shockable rhythm of VF (ventricular fibrillation) or pulseless VT (ventricular tachycardia)\n6. Minimum of ≥ 10 min of ACLS without ROSC or at least ≥ 3 defibrillations in ongoing VF\u002Fpulseless VT\n7. Body morphology able to accommodate a mechanical chest compression device\n8. ECPR team and intensive care unit (ICU) capacity in the receiving center available\n9. Estimated transfer time from the scene to the hospital ≤ 30 minutes or to the scene ≤ 30 minutes\n10. Eligible for intensive care without restrictions or limitations\n\nExclusion Criteria:\n\n1. ACLS ≥ 30 minutes before randomization\n2. Known limitations in care or a Do Not Attempt to Resuscitate (DNAR) order\n3. Known severe disease making 90-day survival unlikely\n4. Known bleeding diathesis or acute or recent intracranial bleeding\n5. Known, obvious or suspected pregnancy\n6. Known pre-arrest severe cognitive dysfunction (mRS ≥ 4)\n7. Known hypothermia as a cause of cardiac arrest",{"count":281,"type":20},686,[104],"The OSIRIS trial is an investigator-initiated, multicenter, multinational, open-label, randomized controlled trial with a 2:1 concealed allocation of refractory out-of-hospital cardiac arrest (OHCA) patients to the extracorporeal cardiopulmonary resuscitation (ECPR) based approach versus the conventional cardiopulmonary resuscitation (CCPR) approach.",[285,286,287,288,230,289],"Cardiac Arrest","Ventricular Fibrillation","Out-Of-Hospital Cardiac Arrest","Sudden Cardiac Arrest","Extracorporeal Membrane Oxygenation",[291,292,293,294],"cardiac arrest","extracorporeal cardiopulmonary resuscitation","extracorporeal membrane oxygenation","out-of-hospital cardiac arrest","2025-01-30",{"date":297,"type":31},"2025-02-03",{"date":299,"type":20},"2025-02",{"date":301,"type":20},"2030-06",{"name":37,"class":38},{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":99,"minAge":76,"maxAge":127,"enrollmentInfo":311,"targetDuration":4,"studyType":102,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":68},"100553088","spirogym-app-aided-cough-rehabilitation-100553088","NCT06481540","SpiroGym App-Aided Cough Rehabilitation","Effect of the SpiroGym App on Voluntary Cough Strength in Parkinson's Disease","ESApp PD","Inclusion Criteria:\n\n* Diagnosis of Parkinsons disease\n* Stable dopaminergic medication (stable dose for at least 1 month)\n\nExclusion Criteria:\n\n* Other neurological disorders\n* Difficulty complying due to neuropsychological dysfunction (dementia with a score of less - - than 19 on the Montreal Cognitive Assessment)\n* Breathing disorders or diseases\n* Smoking in the past 5 years\n* Uncontrolled hypertension",{"count":312,"type":20},60,[104],"The pilot study by Srp et al. (2021) proved that the SpiroGym app was feasible for supporting expiratory muscle strength training (EMST) in Parkinson's disease (PD) patients. Two weeks of intensive EMST coupled with SpiroGym were sufficient to significantly improve the participants' voluntary peak cough flow (PCF). The improvement was quantitatively comparable to the results of other intensive EMST studies with longer durations. When interpreting such rapid improvement, the impact of SpiroGym's visual feedback was considered. It was assumed that visual feedback increased training effort compared to regular training without immediate control. However, comparative studies were required to verify the possible additional effects of visual feedback on voluntary PCF compared to EMST without feedback.",[133,316,317],"Voluntary Peak Cough Strength","mHealth","2025-01-21",{"date":320,"type":31},"2025-01-23",{"date":322,"type":31},"2024-01-01",{"date":324,"type":20},"2025-05",{"name":37,"class":38},{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":102,"phases":334,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":68},"100502027","lifestyle-modification-in-the-treatment-of-nafld-100502027","NCT05816915","Lifestyle Modification in the Treatment of NAFLD.","Complex Lifestyle Modification in the Treatment of Non-alcoholic Fatty Liver Disease","Inclusion Criteria:\n\n* Individuals with NAFLD and metabolic syndrome\n\nExclusion Criteria:\n\n* Etiology of liver disease other than NAFLD.\n* Presence of malignant disease.\n* Uncontrolled cardiovascular disease\n* Pregnancy.",{"count":173,"type":20},[104],"The project will study the impact of individually tailored lifestyle counselling compared to standard care on the parameters of NAFLD\u002FNASH in patients with metabolic syndrome. The factors affecting the outcome (including clinical and laboratory parameters and microbiome profiling) will be evaluated.",[337],"NAFLD",[337,339],"Cognitive behavioral therapy","2024-09-23",{"date":342,"type":31},"2024-09-25",{"date":344,"type":31},"2023-08-30",{"date":346,"type":20},"2026-12",{"name":37,"class":38},{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":68},"100517664","molecular-markes-of-fibrosis-of-endometriosis-and-their-use-in-predicting-disease-severity-100517664","NCT06020482","Molecular Markes of Fibrosis of Endometriosis and Their Use in Predicting Disease Severity","Molecular Markes of Fibrosis of Single Types of Endometriosis and Their Use in Predicting Disease Severity","MMF","Inclusion Criteria:\n\n* women (18-45 years)\n* signed informed consent with the study\n* absence of hormonal treatment 3 months before the planned procedure\n\nInclusion criteria for group A:\n\n\\- laparoscopically and histologically confirmed endometriosis dg.\n\nInclusion criteria for group B:\n\n* patients without endometriosis\n* patients who are undergoing an elective laparoscopic or hysteroscopic procedure in our department for another benign indication\n* patients with excluded malignant disease\n\nExclusion Criteria:\n\n* absence of informed consent\n* patients who do not meet the inclusion criteria during surgery\n* patient younger than 18 years of age or older than 45 years of age","45 Years",{"count":48,"type":20},"The primary aim of the project is to analyse gene expression in individual types of ectopic endometrium (ovarian endometriosis, peritoneal endometriosis, deep infiltrating endometriosis) and compare it with gene expression in eutopic endometrium. The analysis focuses on the identification of genes with significantly increased expression in each type of ectopic endometrium and comparison of their expression with the degree of disease, ovarian reserve and clinical manifestations of the disease (pain, infertility).",[360],"Molecular Markers of Fibrosis of Single Types of Endometriosis and Their Use in Predicting Disease Severity",[362],"endometriosis, moleculars markers of fibrosis, deep infiltrating endometriosis","2023-08-28",{"date":365,"type":31},"2023-08-31",{"date":367,"type":31},"2023-04-01",{"date":369,"type":20},"2026-12-31",{"name":37,"class":38},{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":378,"minAge":17,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":102,"phases":381,"briefSummary":383,"conditions":384,"keywords":386,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":4},"100457129","phase-3-early-salvage-therapy-for-patients-with-advanced-features-for-biochemical-relapse-after-radical-prostatectomy-for-localized-prostate-carcinoma-in-correlation-with-supposed-molecular-genetic-parameters-of-higher-aggressiveness-100457129","NCT05232578","Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness","ESTABLISH","Inclusion Criteria:\n\n* \\> 18 years of age\n* Pathologically confirmed invasive prostate carcinoma with minimal 1 risk factor (RF) after radical prostatectomy (RP)\n* Patient refuses the adjuvant therapy after normalization of urinary function within 6 month after RP\n* Signed informed consent to participate in the study and (where necessary) consent to participate in the translational part of the research (not a requirement)\n* ECOG 0 - 1\n* pT2 and minimal 1 risk factor (RF):\n\n  * R1 (PSM), and\u002For\n  * Gleason score (4+3=7) 8-10 and\u002For ISUP grade group 3-5\n* pT3a \u002FpT3b with or without one RF\n* No evidence of suspicious pelvic lymph nodes by initial diagnostic: cN0 and\u002For pN0\n* No evidence of suspicious distant metastases by initial diagnostic: M0\n* Patient with decline of PSA level to undetectable PSA levels (\\\u003C 0,1 ng\u002Fml) or around 0,2ng\u002Fml and with another decreasing trends so that the PSA level decline within 12-24 weeks after RP to undetectable levels (\\\u003C 0,1 ng\u002Fml) and with renewed increase of PSA \\>0,2 ng\u002Fml (BCR= biochemical relapse) without any clinical relapse on PSMA PET\u002FCT\n* No hormonal therapy prior and \u002For after the radical prostatectomy\n* Patient suitable and fit for subsequent radiotherapy with high likelihood of good compliance to the follow-up\n\nExclusion Criteria:\n\n* Life expectancy (based on Charlson comorbidity index) \\\u003C 10 years\n* Patient not fit for the therapy\n* History of other cancer (other than a radically removed non-melanoma skin carcinoma)\n* Previous pelvic irradiation\n* Active immunosuppressive medication\n* History of hormone therapy prior to randomization\n* cN1 and\u002For pN1 and M1\n* PSA-persistence after RP (PSA 12-weeks after RP \\> 0.1 ng\u002Fml or no decreasing trend described in Inclusion criteria)","MALE",{"count":380,"type":20},380,[382],"PHASE3","The primary objective of the trial is to compare the impact and safety of delayed salvage therapy (dSRT, i.e., SRT initiated at PSA values of 0.4-0.5 ng\u002Fml) to those of early salvage therapy (eSRT, i.e., at PSA levels of 0.2 ng\u002Fml) in patients with biochemical relapse after radical prostatectomy.\n\nThe secondary objective of the trial is to perform analysis of the subgroups of patients to determine which patients are most likely to benefit from dSRT\n\nExploratory objective of the trial is to determine whether selected molecular genetic parameters (172 candidate genes and molecular alterations) and known clinical parameters can be used to identify potential predictors of worse prognosis in patients with known risk factors for relapse after radical prostatectomy, thereby augmenting and refining patient stratification, optimizing their therapy, and clarifying the proper timing of multimodal therapy",[385],"Prostate Cancer",[387,388,389],"prostate carcinoma","salvage therapy","biochemical relapse","2022-08-02",{"date":392,"type":31},"2022-08-03",{"date":394,"type":20},"2022-09",{"date":396,"type":20},"2032-12",{"name":37,"class":38},""]